AbbVie reports veliparib’s Phase II study results for NSCLC

1st June 2015 (Last Updated June 1st, 2015 18:30)

AbbVie has revealed the Phase II study results of the investigational medicine veliparib in patients with non-small cell lung cancer (NSCLC).

AbbVie has revealed the Phase II study results of the investigational medicine veliparib in patients with non-small cell lung cancer (NSCLC).

The veliparib combined with the chemotherapy regimen carboplatin and paclitaxel demonstrated an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced NSCLC who are current smokers.

Veliparib is an investigational oral poly is an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, which is being assessed to treat various cancer types, including NSCLC.

AbbVie oncology clinical development vice president Dr Gary Gordon said: "The results from this study reinforce AbbVie's continued investigation of veliparib in treating advanced non-small cell lung cancer, including patients with a history of smoking."

The Phase II trial assessed survival outcomes in previously untreated metastatic or advanced NSCLC patients treated with either a regimen consisting of a carboplatin, paclitaxel (C/P) or carboplatin, paclitaxel combined with veliparib (V+C/P).

The study also evaluated patients based on their smoking status and each experimental arm of the 158 patient study comprised current smokers, former smokers and non-smoker subgroups.

According to the firm, current smokers treated with V+C/P had a median PFS of 5.6 months compared against 3.3 months for patients treated with C/P alone and non-smokers treated with V+C/P had a median PFS of 6.4 months compared to 5.6 months in patients treated with C/P alone.

In addition, current smokers treated with V+C/P had a median overall survival of 12.5 months compared to 5.4 months for patients treated with C/P alone and former smokers treated with V+C/P had a median overall survival of 8.6 months compared to 14.67 months with those treated with C/P alone, the company said.